Olema Pharmaceuticals is developing palazestrant, an oral SERD in phase 3 trials for ER+/HER2- metastatic breast cancer. Read why OLMA stock is a Hold.

An enzyme called cyclin-dependent kinase 2 (CDK2) regulates the cell cycle and may have the potential to drive therapeutic ...

Pfizer's oncology business reported strong growth in Q4 as the firm looks ahead to further expansion of its breast cancer and antibody-drug conjugate franchises alongside potential financial impacts ...

The phase INAVO120 trial has been evaluating the drug in combination with Pfizer’s CDK4/6 inhibitor Ibrance (palbociclib) and AstraZeneca’s hormone therapy Faslodex (fulvestrant) in patient with ...

Among patients with PIK3CA-mutated, HR-positive, HER2-negative, endocrine-resistant, locally advanced or metastatic breast cancer, treatment with Itovebi (inavolisib) plus Ibrance (palbociclib) and ...

This week, Roche reported that the Phase III INAVO120 trial, testing Itovebi with Pfizer's CDK4/6 inhibitor Ibrance (palbociclib) and fulvestrant in patients with PIK3CA-mutated, hormone receptor (HR) ...

Further results from the randomised, double-blind trial (NCT04191499) showed that Itovebi, otherwise known as inavolisib, when used in combination with Ibrance (palbociclib) and Faslodex ...

in combination with palbociclib (Ibrance ®) and fulvestrant for people with PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, endocrine ...

The Phase III INAVO120 trial found that a combination of Itovebi (inavolisib) with Ibrance (palbociclib) and Faslodex (fulvestrant) significantly improved overall survival and progression-free ...